1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222
Phase 1UNKNOWN 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19, SARS-CoV-2 Infection
Trial Timeline
Oct 10, 2021 โ Jun 1, 2024
NCT ID
NCT05007275About 1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222
1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222 is a phase 1 stage product being developed by AstraZeneca for Covid19. The current trial status is unknown. This product is registered under clinical trial identifier NCT05007275. Target conditions include Covid19, SARS-CoV-2 Infection.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05007275 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Covid19